2026-02-13
[SUZHOU, China | February 13, 2026] —Suzhou Genhouse Bio Co., Ltd. (Genhouse), a China-based biotech company focused on innovative oncology therapies, today announced that it has entered into a definitive agreement with Gilead Sciences, Inc. (Nasdaq: GILD) (Gilead) for GH31, an IND-cleared synthetic lethality oncology program developed by Genhouse.
Under the terms of the agreement, Gilead will gain the worldwide rights to develop and commercialize GH31. Genhouse will receive an $80 million upfront payment and is eligible to receive additional milestone payments associated with development, regulatory, and commercialization milestones of up to $1.45 billion, as well as tiered royalties on net sales up to low double digits.
GH31 is a biomarker-driven synthetic lethality therapy targeting MAT2A, with potential application across multiple tumor types. The program has received IND clearance in the United States and China, enabling immediate advancement into global clinical development. Gilead will assume full global responsibility for GH31, including development, regulatory submissions and future commercialization.
"This transaction represents a significant value-realization milestone for Genhouse and highlights the global attractiveness of our synthetic lethality innovation," said Dr. Kuifeng Wang, CEO of Genhouse. "With IND clearance in hand, GH31 is well positioned for rapid clinical advancement, and we believe Gilead is ideally suited to maximize its global potential for patients."
"The addition of GH31 reflects our disciplined approach to expanding Gilead’s oncology pipeline through innovative science and strong partnerships," said Jackson Egen, Senior Vice President Oncology Research, Gilead Sciences. "We are excited to partner with Genhouse to unlock the full global potential of this program."
About Genhouse
Suzhou Genhouse Bio Co., Ltd. is a clinical-stage biotech company based in China dedicated to the discovery and development of innovative therapies for cancer. The company leverages its combination of research platforms to advance a pipeline of differentiated drug candidates for global markets.
Genhouse Bio (Suzhou) Ltd. (“Genhouse” or “We”) respects the privacy of visitors (“Users”) to our website www.genhousebio.com (“Site”), so we have developed this website privacy statement (“Privacy Statement”). This Privacy Statement indicates what information we collect about you and how that information is used. We may update the content of the Privacy Statement and suggest reading it regularly when you visit our Site.
Personal Information Collected by Genhouse
When you visit the Site, usually we will not collect any personal information from you. We might track your DNS and analyze the data to obtain understanding on visit trends. However, your identity will always remain anonymous, unless you specifically and knowingly provide it to us. When you provide such information, we will collect your personal information, such as when you contact us through the phone number or email address posted on the Site. But no matter when and how we collect your personal information, we will always provide link to this Privacy Statement. By willingly providing your personal information to us, you make the consent that we could use the information collected according to this Privacy Statement and admit that the information will be transferred from your locale to our office or server.
Information Disclosures and Sharing
Except as provided below, we will not share or sell your Personal Information with third parties unless otherwise stated by this Privacy Statement.
We might share your information according to this Privacy Statement, with Related Party who have consented to follow this Privacy Statement. Your personal information might also be transferred to other Related Party who represents us for purpose stated when we collect those information or other purposes permitted by law, such as Site evaluation, data management or technical support.
We might sell or buy business or assets during our operation. If Genhouse is acquired, merged, reorganized or dissolved or other alike situations happened, personal information might be part of the assets transferred. We may share personal information to respond to duly authorized subpoenas or other lawful information requests of governmental authorities, including to meet national security or law enforcement requirements, to provide Internet security, or where required by law.
Cookies
We might put a digital tag (more precisely “cookies”) on your hard disk driver for the server to recognize your computer and track usage information. Cookies will not reveal your personal information and you could always stay anonymous to us. The information we collected from Cookies will only be used for internal purpose and improve the service we provided to you through the Site. Users of our Site always have the option of disabling cookies via their browser preferences. If under any circumstances we collected your personal information, we will always inform you with your planned usage, contact and any Third Party that might get this information. All your personal information will maintain secrecy.
Links to Other Websites
If you apply to a job through our Site, you might be directed to other websites operated by Third Party. This Privacy Statement does not extend to any of these websites. Genhouse will not be responsible for any personal information collected by these websites operated by Third Party. Therefore, for any cases that a Third Party collect or use your personal information, Genhouse will not be legally responsible. We advise you to contact those websites directly and get their policies on personal information collection, safety, sharing and disclosure.
Contact Information
If you have any questions about our Privacy Statement, please do not hesitate to contact us at [infor@genhousebio.com].
Effective and Last Updated: April 15th 2021
